Subcutaneous Daratumumab Plus Carfilzomib and Dexamethasone (D-Kd) in Relapsed/Refractory Multiple Myeloma: An Open-label, Multicenter, Phase 2 Study (PLEIADES)

Abstract

Daratumumab, a human CD38-targeting monoclonal antibody, is approved in many countries for use as monotherapy in relapsed/refractory multiple myeloma (RRMM), and in combination with standard-of-care (SOC) regimens in RRMM and newly diagnosed multiple myeloma. A subcutaneous formulation of daratumumab (DARA SC; co-formulated with recombinant human hyaluronidase PH20 [rHuPH20]; ENHANZE® drug delivery technology, Halozyme, Inc.) was shown to be noninferior to DARA IV, demonstrating similar efficacy and pharmacokinetics, with a decreased rate of infusion-related reactions (IRR) and a reduced administration time.